Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer
Longer-term survival results underscoring role of KEYTRUDA® (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189) Seven-year survival from SOLO-1 and final overall survival (OS) results from PAOLA-1 highlight role of LYNPARZA® (olaparib) in first-line maintenance of advanced ovarian cancer First presentation of KEYTRUDA in combination with an antibody-drug conjugate (enfortumab … [Read more…]
